- Home
- EAF vs AARD Comparison
EAF vs AARD Comparison
Compare EAF & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAF
- AARD
- Stock Information
- Founded
- EAF 1886
- AARD 2017
- Country
- EAF United States
- AARD United States
- Employees
- EAF N/A
- AARD N/A
- Industry
- EAF Industrial Machinery/Components
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- EAF Energy
- AARD Health Care
- Exchange
- EAF Nasdaq
- AARD Nasdaq
- Market Cap
- EAF 169.7M
- AARD 154.9M
- IPO Year
- EAF 1995
- AARD 2025
- Fundamental
- Price
- EAF $0.56
- AARD $7.12
- Analyst Decision
- EAF Hold
- AARD Strong Buy
- Analyst Count
- EAF 6
- AARD 4
- Target Price
- EAF $1.68
- AARD $31.50
- AVG Volume (30 Days)
- EAF 2.8M
- AARD 129.3K
- Earning Date
- EAF 04-25-2025
- AARD 01-01-0001
- Dividend Yield
- EAF N/A
- AARD N/A
- EPS Growth
- EAF N/A
- AARD N/A
- EPS
- EAF N/A
- AARD N/A
- Revenue
- EAF $538,782,000.00
- AARD N/A
- Revenue This Year
- EAF $0.09
- AARD N/A
- Revenue Next Year
- EAF $23.33
- AARD N/A
- P/E Ratio
- EAF N/A
- AARD N/A
- Revenue Growth
- EAF N/A
- AARD N/A
- 52 Week Low
- EAF $0.52
- AARD $4.88
- 52 Week High
- EAF $2.53
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- EAF 32.04
- AARD N/A
- Support Level
- EAF $0.59
- AARD N/A
- Resistance Level
- EAF $0.76
- AARD N/A
- Average True Range (ATR)
- EAF 0.10
- AARD 0.00
- MACD
- EAF -0.00
- AARD 0.00
- Stochastic Oscillator
- EAF 1.65
- AARD 0.00
About EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.